Laetitia Collet

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.

Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 23, 2026

Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinoma.

Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 04, 2026

Definition of the catalytic cleft and product profile of a GH5_5 cellulase from Thermoascus aurantiacus.

Definition of the catalytic cleft and product profile of a GH5_5 cellulase from Thermoascus aurantiacus.

Journal: Acta crystallographica. Section D, Structural biology

Published: January 23, 2026

Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis.

Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis.

Journal: Breast (Edinburgh, Scotland)

Published: November 11, 2025

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

Journal: ESMO open

Published: February 12, 2025

Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial.

Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 21, 2024

Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study.

Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study.

Journal: Metabolomics : Official journal of the Metabolomic Society

Published: July 16, 2024

Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.

Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 29, 2024

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges.

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges.

Journal: Frontiers in oncology

Published: December 12, 2023

Gynecological carcinosarcomas: Overview and future perspectives.

Gynecological carcinosarcomas: Overview and future perspectives.

Journal: Bulletin du cancer

Published: March 18, 2023

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.

Journal: BMC cancer

Published: January 13, 2023

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.

Journal: Journal of clinical medicine

Published: December 19, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026